Replies to post #12573 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I think that if they partner Ponatinib with some other company OTHER than Merck, it pretty much takes a buyout off the table IMO.

Any time you have a company with multiple partners, in multiple drugs, it just begins to really complicate matters in M&A.

Not to say it hasn't been done, it's just less likely.

[NP1986]

You make a logical argument, but IMO buyout speculation (especially on message boards) isn't always based on sound reasoning. Case in point is the appointment of the ex-Merck employee.